Phenotypic and Functional Characterisation of Human B-cell Response in Pemphigus
NCT04117529 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2021-01-08
Summary
Pemphigus is a rare autoimmune disease involving skin and mucous membranes characterized by the production of pathogenic autoantibodies directed against desmosomal transmembrane glycoproteins belonging to the cadherin family,responsible for the disruption of desmosomes leading to the acantholysis phenomenon.Two main classical subtypes of pemphigus have been individualized:pemphigus vulgaris and foliaceus,in which pathogenic autoantibodies are directed against desmoglein 3 and 1 respectively.The knowledge about B-cell populations responsible for pemphigus activity increased a lot.In pemphigus patients,B-cell population was shown to comprise auto-reactive B lymphocytes producing antibodies targeting desmogleins,directly responsible for disease activity,and regulatory B lymphocytes.After rituximab treatment,clinical activity was proved to be associated with circulating auto-antibodies high titers and an increase of auto-reactive B-cells,whereas clinical remission was associated with a change in B-cell populations,as B cell repertoire changed from oligoclonal to polyclonal when reconstituting after treatment,with an increase of immatures and transitional B-cells producing IL-10.The mechanisms leading to autoreactive B-cells appearance,the precise role of B-reg in immune tolerance and the factors triggering the imbalance between pro autoimmune and regulatory immune B-cells leading to pemphigus activity remain to be discovered.Polymorphonuclear neutrophil granulocytes(PMN) are the first responders of the immune system to threats by invading microorganisms.Since 2004, PMN were shown to produce neutrophil extracellular traps(NET),structures consisting of decondensed chromatin embedded with histones,granular and cytoplasmic proteins that trap and kill microbes.In lupus recent works demonstrated evidences that NETs components are found in immune complexes responsible for tissue inflammation and that polyclonal activation of B-cell as well as memory B-cell activation could be obtain in presence of immune complexes derived from NET.Besides lupus,other works showed evidence of NETs implication in inflammatory and auto-immune states in rheumatoid arthritis and small vessel vasculitis.The hypotheses is that B-cell activation by NET might not be restricted to autoimmune diseases of which antibodies target NETs components.The aim is to assess the effects on B-cell activation and the phenotypic changes in B-cell population from pemphigus patients after stimulation by NET.
Conditions
- Pemphigus Vulgaris
- Pemphigus Foliaceus
Interventions
- OTHER
-
Blood sample
Collection of 2 blood sample : The first one at the inclusion in the study, the second one between 6 months and 9 months after the inclusion. The sample consists of 2 tubes of EthyleneDiamineTetraAcetic (EDTA) of 7 mL.
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
Assistance Publique - Hôpitaux de Paris
lead OTHER
Principal Investigators
-
Philippe MUSETTE, Pr · Assistance Publique - Hôpitaux de Paris
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-10-22
- Primary Completion
- 2022-07-31
- Completion
- 2022-07-31
Countries
- France
Study Locations
More Related Trials
-
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
NCT05303272 ·Status: UNKNOWN ·Phase: PHASE4
-
Role of Tzanck Smear in Determining Pemphigus Vulgaris Disease Activity
NCT05338112 ·Status: UNKNOWN
-
Rituximab in the Treatment of Patients With Bullous Pemphigoid
NCT00286325 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid
NCT02874079 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
NCT04117932 ·Status: COMPLETED ·Phase: PHASE2
-
A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313.
NCT06663943 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
NCT01211977 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
NCT00656656 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Study of B007 in the Treatment of Pemphigus.
NCT06454357 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
NCT00525616 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
NCT02704429 ·Status: COMPLETED ·Phase: PHASE2
-
Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy
NCT04641884 ·Status: UNKNOWN
-
Use of Infliximab for the Treatment of Pemphigus Vulgaris
NCT00283712 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Cycle of Intravenous Immunoglobulin as Adjuvant to Rituximab in Patients With Pemphigus: A Retrospective Cohort Study at a Tertiary Referral Center
NCT06949241 ·Status: ACTIVE_NOT_RECRUITING
-
The Effects of Tildrakizumab in Treatment of Bullous Pemphigoid
NCT04465292 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
A Study of Bermekimab in Patients With Hidradenitis Suppurativa
NCT03512275 ·Status: COMPLETED ·Phase: PHASE2
-
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
NCT04035733 ·Status: COMPLETED ·Phase: PHASE2
-
Regulatory B Cells and Chronic Immune Thrombocytopenia
NCT02891109 ·Status: COMPLETED
-
Assessment of the 1-year Relapse Rate in Patients with Pemphigus Treated According to the Revised Pemphigus PNDS
NCT06903494 ·Status: COMPLETED
-
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
NCT04206553 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)
NCT04097561 ·Status: RECRUITING ·Phase: PHASE1
-
Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid
NCT00584935 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
NCT04400994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid
NCT02883894 ·Status: COMPLETED
-
Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
NCT04128176 ·Status: WITHDRAWN ·Phase: PHASE3